Diagnostear Technologies Inc

Capital Structure and Liquidity Diagnostear Technologies Inc has a current ratio of 5.69, indicating strong short-term liquidity, with total assets of CAD 3.31 million and total liabilities of CAD 820,000. The company's debt-to-equity ratio is 0.07, reflecting a conservative capital structure with minimal long-term debt. However, the company has a negative net cash position after subtracting total debt, signaling potential liquidity constraints. ### Profitability and Returns The company reported a net loss of CAD 3.32 million and an operating loss of CAD 3.57 million, resulting in a return on equity of -1.33 and a return on assets of -1.00, both significantly below the industry median for Advanced Medical Equipment & Technology firms. These metrics suggest the company is not currently generating returns for shareholders or effectively utilizing its assets. ### Segments and Geographic Exposure Diagnostear Technologies Inc operates through a single reportable segment focused on tear-based ophthalmic diagnostic solutions. The company is based in Israel and does not disclose geographic revenue breakdowns, making it difficult to assess exposure to regional market risks. ### Growth Trajectory The company has not disclosed specific revenue growth projections for the current or next fiscal year. However, its ongoing R&D activities and regulatory readiness efforts suggest a focus on long-term commercialization rather than near-term revenue generation. The absence of capital expenditures and a negative operating cash flow indicate the company is in a pre-revenue development phase. ### Risk Factors The company faces medium liquidity risk due to its negative net cash position and ongoing operating losses. Dilution risk is currently low, as there is no difference between basic and diluted shares outstanding. However, the company may need to raise additional capital to fund operations, which could lead to future dilution. ### Recent Events Recent filings and transcripts indicate the company is engaged in clinical validation and regulatory readiness for its TeaRx™ technology. No significant recent events have been disclosed that would impact the company's financial position or strategic direction.